GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-22 and is reviewed periodically as new material appears.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Experimental studies also often exceed typical environmental exposure levels when exposing animals or cells to concentrations. This makes it difficult to determine if these same effects will happen at lower, more realistic levels of exposure. No threshold in which nanoplastics begin to significantly affect human health has been established.
High Voltage Engineering Corporation (HVEC) was an American manufacturer of particle accelerators and one of the first venture capital-backed startups. HVEC originated at MIT, where physicist Robert Van de Graaff invented a high-voltage electrostatic particle accelerator and his colleague John Trump miniaturized it for cancer radiotherapy. In 1946, Trump organized a company to manufacture these machines, recruiting Van de Graaff and Denis Robinson as co-founders. Production began in a Cambridge automobile garage. The company's early medical devices gave way to large research accelerators after the Sputnik crisis increased governments' investments in nuclear physics. For two decades, HVEC accelerators were the dominant platform for nuclear physics; in the 1970s, nearly 70 percent of experimental papers relied on HVEC machines. The company built 471 accelerators between 1946 and 1981. They were installed at hospitals, universities, and national laboratories in 30 countries, and some remain in active research use. Using these instruments, HVEC subsidiaries introduced new uses of accelerator beams. Ion Physics Corporation demonstrated that ion implantation could precisely control transistor characteristics, a technique now essential to integrated circuit fabrication. Electronized Chemicals Corporation developed methods to crosslink plastics with electron beams, producing the heat-shrink tubing now ubiquitous in electrical wiring. HVEC was one of the first two startups backed by the American Research & Development Corporation, the first modern venture capital fund.
=== Peptic ulcers === Peptic ulcers may be treated with omeprazole. Infection with Helicobacter pylori can be treated by taking omeprazole, amoxicillin, and clarithromycin together for 7–14 days. Amoxicillin may be replaced with metronidazole in patients who are allergic to penicillin.
=== Flowers and berries === When A. chilensis flowers at the end of spring, the white flowers are unisexual and small, eventually yielding a small edible fruit. The small purple-black berries that form are approximately 4 to 6 millimetres (0.16 to 0.24 in) in diameter and contain 4 to 8 angled seeds. A seven-year-old tree can produce up to 10 kilograms (22 lb) of berries per year. With fruit that tastes similar to blackberries, the species is known as the Chilean wineberry, and locally in Spanish as maqui or maque.
Sources: en.wikipedia.org
=== Similar species === It can easily be mistaken for a variety of other members of the genus Tricholoma, such as T. auratum, T. aestuans, T. intermedium, T. sejunctum, and T. sulphureum. Other similar species include Floccularia albolanaripes and F. luteovirens.
== External links == Labor Management Relations Act (PDF/details) as amended in the GPO Statute Compilations collection A film clip "Longines Chronoscope with Fred A Hartley" is available for viewing at the Internet Archive
== Measurement == All the major indicators mentioned in the table are numerically measurable in a laboratory or otherwise but, for many, high values are also injurious to health just as are low values. This affects the exact measurement of positive health. The optimal levels of most of these parameters are not known – thus a scale to exactly measure the level of positive health of a person is yet to be developed. However, there are parameters such as endorphins, semen quality in men, FEV1/FVC ratio, oxygen saturation, bone density, P3 amplitude, and handGrip strength whose increased value progressively indicates a better positive health.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.